Luis Alvarez/DigitalVision via Getty Images I am updating my previous analysis on Cardinal Health (NYSE:CAH) in light of Q4 and Full-Year 2024 earnings, which were released pre-market on Wednesday, August 14th. I previously rated Cardinal Health a buy for the following reasons:  Q3 earnings were strong with the company raising full-year guidance The OptumRx loss was a short-term blip with no change to the long-term investment thesis The specialty pharmaceutical business had the potential to drive even m ...